J Kemnitz. Show Affiliations »
Abstract
Mesh: See more » Endocardium/pathologyGraft Rejection/classificationGraft Rejection/immunologyGraft Rejection/pathologyHeart Transplantation/immunologyHeart Transplantation/pathologyHumansImmunosuppressive Agents/adverse effectsImmunosuppressive Agents/therapeutic useMuromonab-CD3/adverse effectsMuromonab-CD3/therapeutic useMyocardium/pathologyPrognosis
Substances: See more » Immunosuppressive AgentsMuromonab-CD3
Year: 1995 PMID: 7578197
Source DB: PubMed Journal: J Heart Lung Transplant ISSN: 1053-2498 Impact factor: 10.247